Saturday 17 October 2026
Export ABVX’s income statement to Excel — free account
Abivax SA Sponsored ADR
ABVX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 98.8%, free cash flow fell 48.3% and total debt fell 98.5%, each against the same quarter a year earlier.
87.78
4.60
−4.98%
Follow ABVX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(94.19%) | (136.07%) | (154.01%) | (249.78%) | |
| (64.68%) | (86.11%) | (93.56%) | (137.67%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(54.50%) | (68.55%) | (72.05%) | (111.50%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(4.51) | (2.62) | (2.62) | (2.84) | |
Free Cash Flow |
(328.67) | (182.46) | (206.55) | (226.15) | |
Capital Expenditures |
(0.76) | (0.16) | (0.18) | (0.28) | |
| Other line items | |||||
Cash ROIC |
(24.32%) | (16.21%) | (18.97%) | (24.99%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | (0.02) | (0.02) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | (2.20) | (2.36) | (2.00) | |
Operating CF/Net income |
0.95 | 0.48 | 0.54 | 0.49 | |
Depreciation/Fixed assets |
0.95 | 0.51 | 0.65 | 0.84 | |
Capex/Depreciation |
(0.36) | (0.13) | (0.13) | (0.19) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(4.50) | (2.62) | (2.61) | (2.84) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Oct 2026